LOF PARTNERS LLC 4
4 · BIOJECT MEDICAL TECHNOLOGIES INC · Filed Feb 6, 2013
Insider Transaction Report
Form 4
Transactions
- Purchase
Series H Preferred Stock
2013-01-24$10.00/sh+11,388$113,880→ 11,388 totalExercise: $0.04From: 2013-01-24→ Common Stock (3,253,714 underlying) - Purchase
Series H Preferred Stock
2013-01-24$10.00/sh+63,612$636,120→ 63,612 totalExercise: $0.04From: 2013-01-24→ Common Stock (18,174,857 underlying)
Footnotes (4)
- [F1]These securities are owned directly by Life Sciences Opportunities Fund II, L.P. and indirectly by Signet Healthcare Partners, LLC, the general partner of Life Sciences Opportunities Fund II, L.P., James C. Gale, the chief investment officer and manager of Signet Healthcare Partners, LLC, and SMW Investments I, LLC, the controlling member of Signet Healthcare Partners, LLC. Signet Healthcare Partners, LLC, SMW Investments I, LLC, and James C. Gale disclaim beneficial owernship of the reported securities except to the extent of their pecuniary interest therein.
- [F2]These securities are owned directly by Life Sciences Opportunities Fund II (Institutional), L.P. and indirectly by Signet Healthcare Partners, LLC, the general partner of Life Sciences Opportunities Fund II (Institutional), L.P., James C. Gale, the chief investment officer and manager of Signet Healthcare Partners, LLC, and SMW Investments I, LLC, the controlling member of Signet Healthcare Partners, LLC. Signet Healthcare Partners, LLC, SMW Investments I, LLC, and James C. Gale disclaim beneficial owernship of the reported securities except to the extent of their pecuniary interest therein.
- [F3]Series H Convertible Preferred Stock was issued pursuant to the terms of a Purchase Agreement dated as of January 24, 2013. The Shares are convertible at any time by the purchasers into Commn Stock at the rate of $0.035 per share(subject to anti-dilution adjustments) or approximately 285.71 shares. LOF and LOFI paid cash for the shares.
- [F4]None